Cargando…
Fosaprepitant versus aprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: a multicenter, randomized, double-blind, double-simulated, positive-controlled phase III trial
BACKGROUND: To establish the role of antiemetic therapy with neurokinin-1 (NK-1) receptor antagonists (RAs) in Chinese patients associated with cisplatin-base chemotherapy regimens, this study evaluated the efficacy and safety of single-dose intravenous fosaprepitant-based triple antiemetic regimen t...
Autores principales: | Zhang, Zhonghan, Yang, Yunpeng, Lu, Ping, Li, Xiaoqin, Chang, Jianhua, Zheng, Rongsheng, Zhou, Lei, Chen, Shaoshui, Chen, Xiaopin, Ren, Biyong, Gu, Wei, Jiang, Xiaodong, Peng, Jiyong, Huang, Miaolong, Feng, Guosheng, Shen, Peng, Zhang, Qingyuan, Zhang, Baihong, Huang, Yan, He, Jingdong, Chen, Yinglan, Cao, Jingxu, Wang, Hong, Li, Wei, Wan, Huiping, Nan, Kejun, Liao, Zijun, Zhang, Cuiying, Lin, Zhong, Zhong, Diansheng, Xu, Qing, Liu, Hailong, Sun, Tao, Deng, Yanming, Zhang, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154406/ https://www.ncbi.nlm.nih.gov/pubmed/32309381 http://dx.doi.org/10.21037/atm.2019.12.158 |
Ejemplares similares
-
Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting
por: Langford, Patrick, et al.
Publicado: (2010) -
Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
por: Gao, Ai, et al.
Publicado: (2023) -
Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin
por: Zhao, Yuanyuan, et al.
Publicado: (2022) -
Comparison between 5-day aprepitant and single-dose fosaprepitant meglumine for preventing nausea and vomiting induced by cisplatin-based chemotherapy
por: Ando, Yosuke, et al.
Publicado: (2015) -
Efficacy and safety of fosaprepitant in the prevention of nausea and vomiting following highly emetogenic chemotherapy in Chinese people: A randomized, double‐blind, phase III study
por: Yang, L.Q., et al.
Publicado: (2017)